Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel ...

D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

This was the stock's fourth consecutive day of losses.

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

We recently published a list of Jim Cramer’s Must-Watch List: 10 Stocks to Look After. In this article, we are going to take ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...